Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PU-H71 |
Synonyms | |
Therapy Description |
PU-H71 selectively inhibits Heat shock protein 90 (Hsp90), resulting in increased proteosomal degradation of oncogenic client proteins and potentially leading to decreased tumor growth (PMID: 28808818, PMID: 32156599). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PU-H71 | NSC 750424|PUH71|PU H71 | HSP90 Inhibitor 35 | PU-H71 selectively inhibits Heat shock protein 90 (Hsp90), resulting in increased proteosomal degradation of oncogenic client proteins and potentially leading to decreased tumor growth (PMID: 28808818, PMID: 32156599). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01393509 | Phase I | PU-H71 | The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies | Completed | USA | 0 |
NCT03935555 | Phase I | PU-H71 | Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib | Terminated | USA | 0 |
NCT01581541 | Phase I | PU-H71 | PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin s Lymphoma That Have Not Responded to Standard Treatment | Terminated | USA | 0 |